Q-omics provides the consensus-scored PTGES3L profile across patient tissues and cancer cell-line models. PTGES3L expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PTGES3L is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, PTGES3L RNA expression shows 17,728 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KICH, BLCA, and LIHC as cancer lineages where PTGES3L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTGES3L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTGES3L survival associations across molecular data types. PTGES3L RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTGES3L RNA expression–survival associations across cancer types. High PTGES3L expression shows unfavorable associations in KICH, KIRC, MESO and UVM, but favorable associations in PAAD and LUSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for PTGES3L RNA expression.
This table summarizes PTGES3L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PTGES3L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTGES3L shows lower tumor expression in BLCA, KIRC, KICH and THCA and higher tumor expression in LUAD and LIHC. The BLCA box plot shows higher PTGES3L RNA expression in normal versus tumor tissue (log2 FC = −2.860, t-test p < 0.001).
This table shows molecular features associated with PTGES3L in patient tissues and cancer cell lines. In patient samples, PTGES3L shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTGES3L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
